Post-Brexit point-based immigration system will affect the UK’s healthcare system: Poll
Verdict conducted a poll to analyse the impact of the post-Brexit points-based immigration system on the UK’s healthcare system.
Pharmaceuticals
Cell and gene therapy: the impact of skills gaps in a fast-growing sector
Cell and gene therapy is a rapidly evolving experimental space that saw almost £20bn in...
US pharma lobby reaches out to patients and politicians with drug access campaign
US industry association the Pharmaceutical Research and Manufacturers of America (PhRMA) has released a series of policies it says will...
Common asthma drug speeds up Covid-19 recovery at home, study finds
Oxford University researchers have found that a cheap asthma drug can help speed up recovery for people at home with...
Sanofi and C4X Discovery enter licensing deal worth up to €414m
Sanofi and drug discovery company C4X Discovery (C4XD) have entered an exclusive worldwide licensing agreement worth up to €414m for...
AZ Covid-19 vaccine and blood clots: the risks explained
In mid-March, a number of European countries paused their rollout of the AstraZeneca (AZ) Covid-19 vaccine after reports of blood clots in a small number of those who received the…
UK rollout of Moderna Covid-19 vaccine begins in Wales
Moderna’s Covid-19 vaccine rollout has begun in the UK, where patients in Wales have been the first to receive a dose. Supplies arrived in Wales on Tuesday, with 5,000 doses…
EC approves Novartis’s Kesimpta for relapsing multiple sclerosis
The European Commission has approved Novartis’s Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults with active disease defined by clinical or imaging features. Kesimpta…
EC approves Roche’s Evrysdi as first at-home treatment for spinal muscular atrophy
The European Commission has granted marketing authorisation to PTC Therapeutics’ Evrysdi (risdiplam) for the at-home treatment of spinal muscular atrophy (SMA) in patients aged two months and older. The drug,…
Potential for expanded patient access to novel rare disease therapeutics as a result of SalioGen Therapeutics’ non-viral gene therapy platform
SalioGen Therapeutics has raised $20m to support preclinical validation of its platform, Exact DNA Integration Technology (EDIT), for developing non-viral vector gene therapies using the enzyme saliogase, which SalioGen has…
Pfizer/BioNTech’s Comirnaty forecast to reach record-breaking peak sales within two years of launch
Pfizer/BioNTech’s Comirnaty (tozinameran) is forecast to have greater peak sales than the world’s largest blockbuster, Abbvie’s rheumatoid arthritis drug Humira (adalimumab), by its second year of being on the market.…
